Clinical Trial

A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich Ataxia

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to assess the long-term safety of vatiquinone in participants with Friedreich ataxia (FA) previously exposed to vatiquinone.
Protocol Amendment History 28 amendments
This ClinicalTrials.gov record has been amended 28 times since 2022-08-23; most recent amendment 2025-10-29.
Status change: Enrolling by Invitation → Active, Not Recruiting 2025-01-27
Status change: Not Yet Recruiting → Enrolling by Invitation 2023-02-27
Trial Details
NCT Number NCT05515536
Lead Sponsor PTC Therapeutics
Conditions Friedreich Ataxia
Enrollment 130 participants
Start Date 2022-12-08
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-10-30